Latigo Biotherapeutics

Develops selective small-molecule NaV1.8 inhibitors designed to block peripheral pain transmission without opioid pathways. The clinical portfolio comprises LTG-001 for moderate-to-severe acute and postoperative pain and LTG-321 for chronic musculoskeletal pain; LTG-418 and other ion-channel modulators remain preclinical or in discovery. Development pairs internal discovery and translational tools with outsourced clinical trials and third-party manufacturing.

Operates as a single research-and-development segment, with no approved products, product revenue, or internal sales, marketing, and distribution capability. Early clinical studies occurred in New Zealand, while the commercial opportunity is initially framed around the U.S. and FDA approval. LTG-001 depends on a licensed intellectual-property agreement, and all manufacturing, storage, distribution, and quality testing are performed by third parties.